首页> 外国专利> METHOD AND KIT FOR EVALUATING PROGNOSIS, DISTANT RECURRENCE RISK AND INVASION OF GLIOMA, AND PHARMACEUTICAL COMPOSITION FOR TREATING GLIOMA

METHOD AND KIT FOR EVALUATING PROGNOSIS, DISTANT RECURRENCE RISK AND INVASION OF GLIOMA, AND PHARMACEUTICAL COMPOSITION FOR TREATING GLIOMA

机译:评估胶质瘤的预后,远距离复发风险和入侵以及治疗胶质瘤的药物成分的方法和工具包

摘要

[Problem];The present invention addresses the problem of providing a novel biomarker which makes it possible to find the prognosis of a glioma, the risk of distant recurrence of a glioma, the invasion ability of glioma cells and the like and also makes it possible to detect the prognosis, the risk, the invasion ability or the like in an earlier stage of a therapy of glioma.;[Solution];The present invention relates to a method for evaluating the prognosis of a glioma, said method comprising the steps of: detecting ACTC1 protein and/or mRNA encoding the protein in a glioma-containing sample collected from a patient; and determining that the prognosis of the glioma is poor when the ACTC1 protein and/or the mRNA encoding the protein is detected in the aforementioned step. According to the present invention, the prognosis of a glioma, the risk of distant recurrence of a glioma, the invasion ability and the like can be evaluated using a novel biomarker, i.e., ACTC1 protein and/or mRNA encoding the protein.
机译:[问题];本发明解决了提供新颖的生物标记物的问题,该生物标记物使得可以发现神经胶质瘤的预后,神经胶质瘤远距离复发的风险,神经胶质瘤细胞的侵袭能力等,并且还使得有可能检测神经胶质瘤治疗的早期阶段的预后,风险,侵袭能力等。[解决方案]本发明涉及一种评估神经胶质瘤的预后的方法,所述方法包括以下步骤: :在从患者收集的含神经胶质瘤的样品中检测ACTC1蛋白和/或编码该蛋白的mRNA;当在上述步骤中检测到ACTC1蛋白和/或编码该蛋白的mRNA时,确定神经胶质瘤的预后不良。根据本发明,可以使用新型生物标志物,即ACTC1蛋白和/或编码该蛋白的mRNA,来评估神经胶质瘤的预后,神经胶质瘤远距离复发的风险,侵袭能力等。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号